Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs United Airlines Holdings Inc (UAL) Price & Performance

ADMA Biologics IncTrade
United Airlines Holdings IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs United Airlines Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.93 (market cap $2.22B), while United Airlines Holdings Inc trades at $124.93 (market cap $41.00B). The key difference: United Airlines Holdings Inc is far larger — about 18.5× ADMA Biologics Inc's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMAUAL
Market Cap
$2.22B$41.00B
Sector
HealthIndustrials
52-Week High
$20.38$136.11
52-Week Low
$7.60$85.21
Enterprise Value
$2.29B$58.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

United Airlines Holdings Inc

United Airlines (UAL) trades at $123.76, down 4.48% today, but maintains a bullish technical signal with strong analyst support. The stock shows robust fundamentals, including a P/E of 11.83, net income margin of 5.56%, and three consecutive quarterly EPS beats. Revenue growth is steady, rising to $59.07B in 2025, with cash flow from operations at $8.43B. Recent news highlights CEO Scott Kirby's focus on innovation after merger attempts failed, while industry-wide fuel cost pressures are being managed.

Outlook remains positive with a consensus price target of $167.73, implying 35% upside. Opportunities include strong travel demand and operational efficiency, but risks involve volatile fuel prices, competitive pressures, and execution challenges. Wall Street sentiment is bullish with 66% buy ratings and no sell recommendations, supporting a favorable risk-reward profile for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About United Airlines Holdings Inc

United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.

Read more on UAL